| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA848: Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | cemiplimab (Libtayo®) |
| Formulation | 350 mg concentrate for solution for infusion |
| Reference number | 3617 |
| Indication | First-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have: locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC |
| Company | Sanofi |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/06/2021 |
| NICE guidance | TA848: Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer |